Decreased Regulatory T Cells in Vulnerable Atherosclerotic Lesions: Imbalance between Pro- and Anti-Inflammatory Cells in Atherosclerosis

Table 3

Antibodies used for immunohistochemical analyses.

Antibodies	Source	Dilution	Specificity
CD86	Milteyi Biotec	1 : 25	APCs
CD68	Dako	1 : 50	Macrophages
S-100	Dako	1 : 500	Glial Cells, ependyma, Schwann cells, mDCs
Fascin	Dako	1 : 100	mDCs
CD83	Serotec	1 : 40	Mature mDCs
CD209	BD Pharmingen	1 : 100	Immature mDCs
CD304	Miltenyi Biotec	1 : 100	pDCs
CD123	Serotec	1 : 100	pDCs
HLA-DR	Dako	1 : 25	APCs
CD3	Miltenyi Biotec	1 : 100	T cells
CD4	Dako	1 : 50	T helper cells
CD8	Dako	1 : 200	Cytotoxic T cells
CD161	Serotec	1 : 20	Natural killer cells
CD25	Invitrogen	1 : 20	Activated B and T cells, regulatory T cells
CD69	Ab cam	1 : 100	Activated B and T cells, regulatory T cells (early activation marker), macrophages, and platelets
FoxP3	BioLegend	1 : 20	Regulatory T cells
CD34	Dako	1 : 50	Endothelial cells
CCR4	BioLegend	1 : 50	Chemokine receptor of DC, T cells, and B cells
CCR-6	R&D	1 : 80	Chemokine receptor of immature DCs

APC: antigen presenting cell; mDCs: monocytoid dendritic cells; pDCs: plasmacytoid dendritic cells.